日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

High-resolution array comparative genomic hybridization of single micrometastatic tumor cells

MPS-Authors
/persons/resource/persons50488

Reinhardt,  Richard
High Throughput Technologies, Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
There are no locators available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)

e39.pdf
(全文テキスト(全般)), 2MB

付随資料 (公開)
There is no public supplementary material available
引用

Fuhrmann, C., Schmidt-Kittler, O., Stoecklein, N. H., Petat-Dutter, K., Vay, C., Bockler, K., Reinhardt, R., Ragg, T., & Klein, C. A. (2008). High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Research, 36(7), e39-e39. doi:10.1093/nar/gkn101.


引用: https://hdl.handle.net/11858/00-001M-0000-0010-8034-8
要旨
Only few selected cancer cells drive tumor progression and are responsible for therapy resistance. Their specific genomic characteristics, however, are largely unknown because high-resolution genome analysis is currently limited to DNA pooled from many cells. Here, we describe a protocol for array comparative genomic hybridization (array CGH), which enables the detection of DNA copy number changes in single cells. Combining a PCR-based whole genome amplification method with arrays of highly purified BAC clones we could accurately determine known chromosomal changes such as trisomy 21 in single leukocytes as well as complex genomic imbalances of single cell line cells. In single T47D cells aberrant regions as small as 1–2 Mb were identified in most cases when compared to non-amplified DNA from 106 cells. Most importantly, in single micrometastatic cancer cells isolated from bone marrow of breast cancer patients, we retrieved and confirmed amplifications as small as 4.4 and 5 Mb. Thus, high-resolution genome analysis of single metastatic precursor cells is now possible and may be used for the identification of novel therapy target genes.